The patients 16 years or older who receive umbilical cord blood transplant as the first allogeneic hematopoietic cell transplantation for the treatment of hematologic malignancies (blood cancers) .
Conditions
Interventions
Foscarnet administration
Sponsors
Research team to establish the efficacy of allogeneic stem cell transplantation for adult T cell leukemia, and optimize the treatment based on genome analysis. JSHCT
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who receive umbilical cord blood transplantation as the first allogeneic stem cell transplantation for the treatment of hematologic malignancies (blood cancers). 2. Patient 16 years or older. 3. Written informed consent. If patient is less than 20 years, written informed consent from both patient and patient's parent/guardian is required.
Exclusion criteria
Exclusion criteria: 1. Patient who have allergy against foscarnet. 2. Patient whose creatinine clearance <0.8 mL/min/kg 3. Patient who is judged as inappropriate to participate this study by any reasons. Medical doctor participating this study make this decision.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative incidence of plasma HHV-6 DNA>=10,000 copies/ml at 60 days after transplantation. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Safety 2. Incidence of HHV-6 encephalitis and possible HHV-6 encephalitis within 60 days after transplantation 3. Overall survival at 60 days after transplantation 4. Cumulative incidence of non-repapse mortality, relapse, acute GVHD 5. Relationship between HHV-6 reactivation and administration period of foscarnet 6. Incidence of plasma HHV-6 DNA>=10,000 copies/ml in patients who complete 21 days administration of foscarnet. | — |
Countries
Japan
Contacts
Public ContactMasaaki Kurihara
Non-profit organization Japan Clinical research Support Unit Research support section for Pediatrics/Hematology
Outcome results
None listed